Transgene Announces Promising Results in an Update from the Phase 2b Part of TIME Trial with TG4010 in Advanced Non-Small Cell Lung Cancer

Transgene Announces Promising Results in an Update from the Phase 2b Part of TIME Trial with TG4010 in Advanced Non-Small Cell Lung Cancer

Primary endpoint met with more mature data in normal TrPAL group

In addition, statistically and clinically significant PFS improvement in non-squamous lung cancer patients

Strasbourg, France, May 27, 2014 - Transgene SA (NYSE-Euronext: TNG) today announced promising results in an update incorporating more mature data from the Phase 2b part of the Phase 2b/3 TIME trial with TG4010 MUC-1 targeted immunotherapy in patients with advanced non-small cell lung cancer (NSCLC).

Following an analysis conducted with a more mature dataset, the primary endpoint of progression-free survival (PFS) to validate the TrPAL predictive biomarker was met in the normal TrPAL group. The high TrPAL group had not yet met the required number of events to conduct the primary analysis.